These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32747165)

  • 21. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
    Edmonston DL; South AM; Sparks MA; Cohen JB
    Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
    Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
    J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and renin-angiotensin system modulators: what do we know so far?
    de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
    Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
    Tomasoni D; Italia L; Adamo M; Inciardi RM; Lombardi CM; Solomon SD; Metra M
    Eur J Heart Fail; 2020 Jun; 22(6):957-966. PubMed ID: 32412156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.
    Jiang X; Eales JM; Scannali D; Nazgiewicz A; Prestes P; Maier M; Denniff M; Xu X; Saluja S; Cano-Gamez E; Wystrychowski W; Szulinska M; Antczak A; Byars S; Skrypnik D; Glyda M; Król R; Zywiec J; Zukowska-Szczechowska E; Burrell LM; Woolf AS; Greenstein A; Bogdanski P; Keavney B; Morris AP; Heagerty A; Williams B; Harrap SB; Trynka G; Samani NJ; Guzik TJ; Charchar FJ; Tomaszewski M
    Eur Heart J; 2020 Dec; 41(48):4580-4588. PubMed ID: 33206176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE2: from protection of liver disease to propagation of COVID-19.
    Warner FJ; Rajapaksha H; Shackel N; Herath CB
    Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.
    Khera R; Clark C; Lu Y; Guo Y; Ren S; Truax B; Spatz ES; Murugiah K; Lin Z; Omer SB; Vojta D; Krumholz HM
    J Am Heart Assoc; 2021 Jul; 10(13):e018086. PubMed ID: 33624516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
    Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
    N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19.
    Rocheleau GLY; Lee T; Mohammed Y; Goodlett D; Burns K; Cheng MP; Tran K; Sweet D; Marshall J; Slutsky AS; Murthy S; Singer J; Patrick DM; Du B; Peng Z; Lee TC; Boyd JH; Walley KR; Lamontagne F; Fowler R; Winston BW; Haljan G; Vinh DC; McGeer A; Maslove D; Patrigeon SP; Mann P; Donohoe K; Hernandez G; Russell JA;
    Crit Care Med; 2022 Sep; 50(9):1306-1317. PubMed ID: 35607951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
    Dézsi CA
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.
    Kuzeytemiz M; Tenekecioglu E
    J Investig Med; 2022 Mar; 70(3):786-791. PubMed ID: 34987107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
    Albashir AAD
    South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment.
    Sarı C; Şimşek EÇ; Özdoğan Ö
    J Hum Hypertens; 2021 Oct; 35(10):828-836. PubMed ID: 33168943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.
    Christiansen CF; Heide-Jørgensen U; Rasmussen TB; Bodilsen J; Søgaard OS; Maeng M; Vistisen ST; Schmidt M; Pottegård A; Lund LC; Reilev M; Hallas J; Johansen NB; Brun NC; Sørensen HT; Thomsen RW
    J Am Heart Assoc; 2020 Oct; 9(19):e017297. PubMed ID: 32998607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
    Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW
    Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19.
    Tetlow S; Segiet-Swiecicka A; O'Sullivan R; O'Halloran S; Kalb K; Brathwaite-Shirley C; Alger L; Ankuli A; Baig MS; Catmur F; Chan T; Dudley D; Fisher J; Iqbal MU; Puczynska J; Wilkins R; Bygate R; Roberts P
    J Intern Med; 2021 May; 289(5):688-699. PubMed ID: 33210357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
    Safizadeh F; Nguyen TNM; Brenner H; Schöttker B
    Br J Clin Pharmacol; 2022 Jun; 88(6):2830-2842. PubMed ID: 34935181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
    Matsuzawa Y; Kimura K; Ogawa H; Tamura K
    Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.